Endocrine Abstracts

Aim: Somatostatin mediates its effects via five known receptor subtypes sst1-sst5. The somatostatin analogue octreotide, which binds preferentially to sst2 and to a lesser extent to sst3 and sst5, may be used prior to surgery of GH-secreting tumors. To investigate the variable response rates of such treatment, we analyzed sst expression levels in tumor tissue.Methods: 44 patients with acromegaly (20m, 24f, 48.7+/...

Objective: Therapeutic options for patients with dedifferentiated thyroid carcinoma are rare and alternative treatment strategies are needed. Among the most promising new agents for these patients are protein kinase inhibitors like the BRAF- and multi-targeted kinase inhibitor sorafenib. We have already shown that sorafenib inhibits growth of dedifferentiated thyroid carcinoma cell lines with and without BRAF mutation. The purpose of this study was to analyze the molecular eff...